NeoGenomics, Inc. (NASDAQ:NEO) Receives $12.00 Average PT from Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus rating of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.00.

A number of research firms have weighed in on NEO. Needham & Company LLC upped their target price on NeoGenomics from $8.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, August 29th. TD Cowen lifted their price target on NeoGenomics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Leerink Partners set a $14.00 price target on NeoGenomics in a research note on Tuesday, October 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 8th. Finally, Cowen restated a “buy” rating on shares of NeoGenomics in a report on Friday, September 12th.

NeoGenomics Stock Up 0.7%

Shares of NASDAQ NEO opened at $11.85 on Wednesday. The firm has a fifty day simple moving average of $10.63 and a two-hundred day simple moving average of $8.38. The firm has a market capitalization of $1.53 billion, a PE ratio of -13.47 and a beta of 1.59. The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. NeoGenomics has a 12 month low of $4.72 and a 12 month high of $19.11.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The company had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $183.85 million. During the same quarter in the previous year, the company earned $0.05 earnings per share. NeoGenomics’s quarterly revenue was up 12.0% on a year-over-year basis. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Equities analysts expect that NeoGenomics will post -0.2 earnings per share for the current year.

Insider Buying and Selling

In other NeoGenomics news, EVP Alicia C. Olivo sold 20,916 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the sale, the executive vice president owned 31,083 shares in the company, valued at approximately $372,996. This represents a 40.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd boosted its holdings in NeoGenomics by 42.5% in the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after acquiring an additional 997 shares in the last quarter. Brooklyn Investment Group purchased a new position in shares of NeoGenomics in the 1st quarter worth about $35,000. Headlands Technologies LLC bought a new position in NeoGenomics in the 2nd quarter worth about $32,000. AlphaQuest LLC purchased a new stake in NeoGenomics during the 1st quarter valued at about $60,000. Finally, Capstone Financial Advisors Inc. purchased a new stake in NeoGenomics during the 2nd quarter valued at about $73,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.